Volume 11 Issue 3
May  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(3): 362-368
Liao Tao, Yang Zhe, Zhang Yannan, et al. Establishment and analysis of mouse model of acute antibody-mediated rejection in heart transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 362-368. doi: 10.3969/j.issn.1674-7445.2020.03.007
Citation: Liao Tao, Yang Zhe, Zhang Yannan, et al. Establishment and analysis of mouse model of acute antibody-mediated rejection in heart transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 362-368. doi: 10.3969/j.issn.1674-7445.2020.03.007
shu

Establishment and analysis of mouse model of acute antibody-mediated rejection in heart transplantation

doi: 10.3969/j.issn.1674-7445.2020.03.007

  • Department of Renal Transplantation, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Sun Qiquan, Email: sunqiq@mail.sysu.edu.cn
  • Received Date: 2020-02-15
    Available Online: 2021-01-19
  • Publish Date: 2020-05-15
    Abstract
  •   Objective  To establish a mouse model of acute antibody-mediated rejection (AMR) in heart transplantation and to analyze its characteristics.  Methods  Mouse models of heart transplantation and skin transplantation were established. According to different treatment methods, all animals were divided into the homologous control group, non-sensitized group, pre-sensitized group and pre-sensitized+ ciclosporin group (9 donors and 9 recipients in each group). The graft survival time, donor-specific antibody (DSA) level and pathological manifestations of each group were observed, and the characteristics of rejection were analyzed.  Results  In the homologous control group, the cardiac grafts of the mice survived for a long period of time during the 3-month observation period. The survival time of the cardiac grafts in the non-sensitized group, pre-sensitized group and pre-sensitized+ciclosporin group was (7.0±0.7) d, (2.6±0.5) d and (5.0±0.7) d, respectively. The differences among the groups were statistically significant (all P < 0.01). The DSA level in the pre-sensitized group was significantly elevated than the baseline level at 3 d after heart transplantation, and that in the pre-sensitized+ciclosporin group was remarkably up-regulated at 5 d after heart transplantation, the differences were statistically significant (P < 0.05, P < 0.01). The pathological manifestation of the non-sensitized group was the myocardial cell destruction, the formation of interstitial inflammation, mild C4d deposition and a large amount of CD3 cell infiltration. The pathological manifestations of the pre-sensitized group and the pre-sensitized+ciclosporin group showed myocardial cell destruction, capillary inflammation and a large amount of C4d deposition, whereas the amount of CD3 cell infiltration in the pre-sensitized group was more than that in the pre-sensitized+ciclosporin group.  Conclusions  The use of ciclosporin on the basis of heart transplantation and skin transplantation between different strains of mice can successfully establish a practical acute AMR model in mouse heart transplantation, which provides the basis for subsequent AMR pathogenesis and intervention research.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    PATEL JK, KITTLESON M, KOBASHIGAWA JA. Cardiac allograft rejection[J]. Surgeon, 2011, 9(3):160-167. DOI: 10.1016/j.surge.2010.11.023.
    [2]
    COZZI E, COLPO A, DE SILVESTRO G. The mechanisms of rejection in solid organ transplantation[J]. Transfus Apher Sci, 2017, 56(4):498-505. DOI: 10.1016/j.transci.2017.07.005.
    [3]
    HUSAIN AN, MIRZA KM, FEDSON SE. Routine C4d immunohistochemistry in cardiac allografts: long-term outcomes[J]. J Heart Lung Transplant, 2017, 36(12):1329-1335. DOI: 10.1016/j.healun.2017.09.004.
    [4]
    KFOURY AG, HAMMOND ME, SNOW GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection[J]. J Heart Lung Transplant, 2009, 28(8):781-784. DOI: 10.1016/j.healun.2009.04.035.
    [5]
    LOUPY A, TOQUET C, ROUVIER P, et al. Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection[J]. Am J Transplant, 2016, 16(1):111-120. DOI: 10.1111/ajt.13529.
    [6]
    PEYSTER EG, MADABHUSHI A, MARGULIES KB. Advanced morphologic analysis for diagnosing allograft rejection: the case of cardiac transplant rejection[J]. Transplantation, 2018, 102(8):1230-1239. DOI: 10.1097/TP.0000000000002189.
    [7]
    BRAZA MS, VAN LEENT MMT, LAMEIJER M, et al. Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance[J]. Immunity, 2018, 49(5):819-828. DOI: 10.1016/j.immuni. 2018.09.008.
    [8]
    MAGEE CN, MURAKAMI N, BORGES TJ, et al. Notch-1 inhibition promotes immune regulation in transplantation via regulatory T cell-dependent mechanisms[J]. Circulation, 2019, 140(10):846-863. DOI: 10.1161/CIRCULATIONAHA.119.040563.
    [9]
    WU C, ZHAO Y, XIAO X, et al. Graft-infiltrating macrophages adopt an M2 phenotype and are inhibited by purinergic receptor P2X7 antagonist in chronic rejection[J]. Am J Transplant, 2016, 16(9):2563-2573. DOI: 10.1111/ajt.13808.
    [10]
    ZHAO Y, CHEN S, LAN P, et al. Macrophage subpopulations and their impact on chronic allograft rejection versus graft acceptance in a mouse heart transplant model[J]. Am J Transplant, 2018, 18(3):604-616. DOI: 10.1111/ajt.14543.
    [11]
    ZHANG H, WU J, ZOU D, et al. Ablation of interferon regulatory factor 4 in T cells induces "memory" of transplant tolerance that is irreversible by immune checkpoint blockade[J]. Am J Transplant, 2019, 19(3):884-893. DOI: 10.1111/ajt.15196.
    [12]
    LIAO T, LIU X, REN J, et al. Noninvasive and quantitative measurement of C4d deposition for the diagnosis of antibody-mediated cardiac allograft rejection[J]. EBioMedicine, 2018, 37:236-245. DOI: 10.1016/j.ebiom. 2018.10.061.
    [13]
    LIAO T, XUE Y, ZHAO D, et al. In vivo attenuation of antibody-mediated acute renal allograft rejection by ex vivo TGF-β-induced CD4+Foxp3+ regulatory T cells[J]. Front Immunol, 2017, 8:1334. DOI: 10.3389/fimmu.2017.01334.
    [14]
    ZHAO D, LI S, LIAO T, et al. Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury[J]. Am J Transplant, 2018, 18(5):1083-1095. DOI: 10.1111/ajt.14602.
    [15]
    ZHAO D, LIAO T, LI S, et al. Mouse model established by early renal transplantation after skin allograft sensitization mimics clinical antibody-mediated rejection[J]. Front Immunol, 2018, 9:1356. DOI: 10.3389/fimmu.2018.01356.
    [16]
    COHEN D, COLVIN RB, DAHA MR, et al. Pros and cons for C4d as a biomarker[J]. Kidney Int, 2012, 81(7):628-639. DOI: 10.1038/ki.2011.497.
    [17]
    COLVIN RB, SMITH RN. Antibody-mediatedorgan-allograft rejection[J]. Nat Rev Immunol, 2005, 5(10):807-817. doi: 10.1038/nri1702
    [18]
    VALENZUELA NM, REED EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies[J]. J Clin Invest, 2017, 127(7):2492-2504. DOI: 10.1172/JCI90597.
    [19]
    HAAS M. The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts[J]. Am J Transplant, 2018, 18(12):2849-2856. DOI: 10.1111/ajt.15088.
    [20]
    COLVIN MM, COOK JL, CHANG P, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association[J]. Circulation, 2015, 131(18):1608-1639. DOI: 10.1161/CIR.0000000000000093.
    [21]
    JORDAN SC, AMMERMAN N, CHOI J, et al. Novel therapeutic approaches to allosensitization and antibody-mediated rejection[J]. Transplantation, 2019, 103(2):262-272. DOI: 10.1097/TP.0000000000002462.
    [22]
    WU J, ZHANG H, SHI X, et al. Ablation of transcription factor IRF4 promotes transplant acceptance by driving allogenic CD4+ T cell dysfunction[J]. Immunity, 2017, 47(6):1114-1128. DOI: 10.1016/j.immuni.2017.11.003.
    [23]
    BERRY GJ, BURKE MM, ANDERSEN C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis ofantibody-mediated rejection in heart transplantation[J]. J Heart Lung Transplant, 2013, 32(12):1147-1162. DOI: 10.1016/j.healun.2013.08.011.
    [24]
    KAMAR N, ALLARD J, ADER JL, et al. Cyclosporine-A-based immunosuppression and renal functional reserve in organ-transplant patients[J]. Transplant Proc, 2004, 36(2 Suppl): 248S-250S. https://www.sciencedirect.com/science/article/abs/pii/S0041134503013514
    [25]
    LIDDICOAT AM, LAVELLE EC. Modulation of innate immunity by cyclosporine A[J]. Biochem Pharmacol, 2019, 163:472-480. DOI: 10.1016/j.bcp.2019.03.022.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (416) PDF downloads(46) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return